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Background:  Circulating procoagulant microparticles (MPs) are increased in thrombotic states including atrial fibrillation (AF).Their role in 
predicting cardiovascular events has not been established in AF patients.
Methods:  In 117 patients hospitalized for non valvular AF, the phosphatidylserine content of MPs was measured using a prothrombinase assay.
Cardiovascular (CV) events (composite: stroke, death, heart failure or acute coronary syndrome, ACS) were recorded. The influence of MPs levels on 
the occurrence of a composite endpoint was studied.
Results:  The mean follow-up was 2.4 ± 1.8 years. Median level of MPs, PMP and EMP were respectively 7.3 nmol/l (3.8-15.2), 5.5 nmol/l (2.2-
9.8) and 0.10 nmol/l (0.02-0.20).The mean CHADS2 was 1.3 ± 1.3. At discharge, 81 patients (78%) were prescribed warfarin and 27 patients 
(23%) aspirin.The composite endpoint occurred in 27 patients (23%). The Kaplan-Meier curves did not show any difference between patients with 
MPs, EMP or PMP levels above or under the median values. In the multivariate analysis, no warfarin at discharge (HR 8.54, 95% CI 2.10-34.78, 
p=0.003), no aspirin at discharge (HR 11.92 95% CI 2.68-53.00), permanent AF (HR 9.17, 95% CI 2.17-38.84, p=0.003) and LA dilatation or LV 
dysfunction (HR 5.88, 95% CI 1.08-32.08, p=0.041) were the only predictors of CV events.
Conclusions:  Circulating procoagulant microparticles are not associated with an increased risk of CV events in NVAF. 
